CIPLA vs DRREDDY: Stock Comparison
Head-to-head financial and trading comparison between Cipla Limited (CIPLA) and Dr. Reddy's Laboratories Limited (DRREDDY) in the Pharmaceuticals & Healthcare sector.
CIPLA
NSE: CIPLADRREDDY
NSE: DRREDDYKey Metrics Comparison Table
| Metric | CIPLA | DRREDDY | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹1,344.00 | ₹1,206.20 | — |
| 1-Year Price Return | +9.31% | -2.11% | CIPLA (11.42% higher) |
| 52-Week High | ₹1,477.00 | ₹1,375.70 | — |
| 52-Week Low | ₹1,211.10 | ₹1,135.60 | — |
| 30-Day Annualized Volatility | 15.13% | 20.49% | CIPLA (Steadier) |
| 30-Day Average Daily Volume | 912,248 | 1,725,067 | DRREDDY (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between CIPLA and DRREDDY, which stock gave better returns over the last year?
CIPLA has outperformed DRREDDY over the past 12 months with a gain of 9.31% compared to -2.11%.
Which stock is less volatile: CIPLA or DRREDDY?
CIPLA demonstrated lower price volatility (15.13% annualized) compared to DRREDDY (20.49%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of CIPLA vs DRREDDY?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are CIPLA and DRREDDY direct sector competitors?
Yes, both companies operate within the Pharmaceuticals & Healthcare sector in India and are actively tracked as sector peers by institutional and retail market participants.